60 DEGREES PHARMACEUTICALS, INC.

For the period ended Mar 31, 2025. Filed May 15, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 15, 2025

SXTP$0.52-4.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Condensed Statements of Shareholders’ Equity

CONSOLIDATED CONDENSED STATEMENTS OF SHAREHOLDERS’ EQUITY (UNAUDITED)

Series A Preferred Stock · Common Stock(1) · Additional Paid-In · Accumulated · Accumulated Other Comprehensive · Total Shareholders’ Equity Attributable · Noncontrolling Interest on · Total Shareholders’
	Shares	Amount	Shares	Amount	Capital(1)	Deficit	Income (Loss)	to 60P	Shareholders	Equity
Balance—December 31, 2024	76,480	$9,567,439	566,908	$57	$34,860,590	$(40,527,957)	$135,471	$4,035,600	$(80,594)	$3,955,006
Issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)	-	-	204,312	20	804,326	-	-	804,346	-	804,346
Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)	-	-	300,700	30	908,597	-	-	908,627	-	908,627
Issuance of common stock upon exercise of Pre-Funded Warrants	-	-	385,200	38	1,888	-	-	1,926	-	1,926
Issuance of shares for annual performance bonuses, net of shares withheld for taxes	-	-	15,809	2	103,542	-	-	103,544	-	103,544
Share-based compensation expense	-	-	-	-	142,645	-	-	142,645	-	142,645
Net foreign translation loss	-	-	-	-	-		(9,904)	(9,904)	-	(9,904)
Net loss	-	-	-	-	-	(1,876,549)	-	(1,876,549)	(752)	(1,877,301)
Share rounding adjustment for reverse stock split	-	-	(38)	-	-		-	-	-	-
Balance— March 31, 2025	76,480	$9,567,439	1,472,891	$147	$36,821,588	$(42,404,506)	$125,567	$4,110,235	$(81,346)	$4,028,889

(1)	Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.

Series A Preferred Stock · Common Stock(1) · Additional Paid-In · Accumulated · Accumulated Other Comprehensive · Total Shareholders’ Equity Attributable · Noncontrolling Interest on · Total Shareholders’
	Shares	Amount	Shares	Amount	Capital(1)	Deficit	Income (Loss)	to 60P	Shareholders	Equity
Balance—December 31, 2023	78,803	$9,858,040	96,847	$10	$27,457,373	$(32,580,850)	$135,561	$4,870,134	$(72,038)	$4,798,096
Issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs (Note 6)	-	-	87,683	9	1,898,287	-	-	1,898,296	-	1,898,296
Issuance of common stock upon exercise of Pre-Funded Warrants	-	-	8,326	1	4,994	-	-	4,995	-	4,995
Issuance of shares for RSUs	-	-	3,201	-	-	-	-	-	-	-
Net foreign translation loss	-	-	-	-	-	-	(3,894)	(3,894)	-	(3,894)
Net income (loss)	-	-	-	-	-	430,470	-	430,470	(2,485)	427,985
Balance— March 31, 2024	78,803	$9,858,040	196,057	$20	$29,360,654	$(32,150,380)	$131,667	$7,200,001	$(74,523)	$7,125,478

(1)	Prior periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024 and the 1:5 reverse stock split on February 24, 2025.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.